Zydus Cadila Seeks Human Trial Approval For COVID-19 Antibody Cocktail

Thursday, 27 May 2021Newsdesk

Zydus Cadila has sought regulatory approval for clinical trials of its antibody cocktail to treat mild COVID-19, as India grapples with a shortage of medicines and vaccines needed to effectively tackle a devastating second wave of the pandemic.

New Delhi, 27 May2021

As per news report of NDTV, the treatment candidate, ZRC-3308, was earlier shown to reduce lung damage during animal trials, the drugmaker said, adding it was found to be safe and well-tolerated.The therapy is a cocktail of two monoclonal antibodies, which mimic natural antibodies that the body generates to fight infection."At this juncture, there is a critical need to explore safer and more efficacious treatments to combat COVID," Zydus Cadila's managing director, Sharvil Patel, said in a stock exchange filing.

Source -NDTV